(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 June 2010 (17.06.2010)

PCT

(10) International Publication Number
WO 2010/066840 A1

(51) International Patent Classification:
C07D 498/10 (2006.01) *A61P 3/10* (2006.01)
A61P 29/00 (2006.01) *A61K 31/55* (2006.01)

(21) International Application Number:
PCT/EP2009/066836

(22) International Filing Date:
10 December 2009 (10.12.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08171421.4 12 December 2008 (12.12.2008) EP
61/121,913 12 December 2008 (12.12.2008) US

(71) Applicant *(for all designated States except US)*: **SOLVAY PHARMACEUTICALS B.V.** [NL/NL]; C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **SMID, Pieter** [NL/NL]; c/o Solvay Pharmaceuticals B.V., C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). **MLINARIC, Michael** [DE/DE]; c/o Solvay Pharmaceuticals B.V., C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). **LANGE, Josephus H.M.** [NL/NL]; c/o Solvay Pharmaceuticals B.V., C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). **KOEHLER, Konrad F.** [US/SE]; c/o Solvay Pharmaceuticals B.V., C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). **NUNEZ-GARCIA, Sara** [ES/NL]; c/o Solvay Pharmaceuticals B.V., C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). **WEGENER, Elmar** [DE/DE]; c/o Solvay Pharmaceuticals B.V., C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL).

(74) Agent: **TULP, Martinus Th.M.**; P.O. Box 140, NL-1380 AC Weesp (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

[Continued on next page]

(54) Title: SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS



(1)

(57) Abstract: This invention concerns spiro azepane-oxazolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein the symbols have the meanings given in the specification.

WO 2010/066840 A1

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*